Nasdaq:US$17.65 (-2.22) | HKEX:HK$29.50 (-2.25) | AIM:£2.98 (-0.36)
What We Do

We are an innovative, commercial-stage biopharmaceutical company based in China, striving to create differentiated novel oncology and immunology treatments with potential to be marketed globally.

Over the past 20 years, we have established a fully integrated oncology business, from discovery and development, all the way to manufacturing to commercialization.